267 related articles for article (PubMed ID: 22873215)
1. Non-coding RNAs as therapeutic targets in hepatocellular cancer.
Braconi C; Patel T
Curr Cancer Drug Targets; 2012 Nov; 12(9):1073-80. PubMed ID: 22873215
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies.
Xu XF; Yang XK; Song Y; Chen BJ; Yu X; Xu T; Chen ZL
Pharmacol Res; 2022 Feb; 176():105906. PubMed ID: 34543740
[TBL] [Abstract][Full Text] [Related]
3. Noncoding RNA as therapeutic targets for hepatocellular carcinoma.
George J; Patel T
Semin Liver Dis; 2015 Feb; 35(1):63-74. PubMed ID: 25632936
[TBL] [Abstract][Full Text] [Related]
4. Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.
Hoshida Y; Fuchs BC; Tanabe KK
Curr Cancer Drug Targets; 2012 Nov; 12(9):1129-59. PubMed ID: 22873223
[TBL] [Abstract][Full Text] [Related]
5. [CLINICAL SIGNIFICANCE OF NONCODING RNA IN HEPATOCELLULAR CARCINOMA].
Eguchi H; Doki Y; Mori M
Nihon Geka Gakkai Zasshi; 2015 Nov; 116(6):366-9. PubMed ID: 26845888
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between m6A modification and non-coding RNAs in HCC.
Qiu Z; Yuan X; Wang X; Liu S
Cell Signal; 2024 May; 117():111076. PubMed ID: 38309550
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs and other non-coding RNAs as targets for anticancer drug development.
Ling H; Fabbri M; Calin GA
Nat Rev Drug Discov; 2013 Nov; 12(11):847-65. PubMed ID: 24172333
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNAs in hepatocellular carcinoma: Potential roles and clinical implications.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2017 Aug; 23(32):5860-5874. PubMed ID: 28932078
[TBL] [Abstract][Full Text] [Related]
9. Noncoding RNAs (ncRNA) in Hepato Cancer: A Review.
Sun X; Malhotra A
J Environ Pathol Toxicol Oncol; 2018; 37(1):15-25. PubMed ID: 29772997
[TBL] [Abstract][Full Text] [Related]
10. Targeting non-coding RNAs and N
Wu L; Zhang Y; Ren J
Biochem Pharmacol; 2024 May; 223():116153. PubMed ID: 38513741
[TBL] [Abstract][Full Text] [Related]
11. Dietary phytochemicals in the chemoprevention and treatment of hepatocellular carcinoma: in vivo evidence, molecular targets, and clinical relevance.
Bishayee A; Thoppil RJ; Waghray A; Kruse JA; Novotny NA; Darvesh AS
Curr Cancer Drug Targets; 2012 Nov; 12(9):1191-232. PubMed ID: 22873222
[TBL] [Abstract][Full Text] [Related]
12. Non-coding RNAs in hepatitis B or C-associated hepatocellular carcinoma: potential diagnostic and prognostic markers and therapeutic targets.
Zhang Q; Pu R; Du Y; Han Y; Su T; Wang H; Cao G
Cancer Lett; 2012 Aug; 321(1):1-12. PubMed ID: 22425745
[TBL] [Abstract][Full Text] [Related]
13. Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma.
Heo MJ; Yun J; Kim SG
Arch Pharm Res; 2019 Jan; 42(1):48-62. PubMed ID: 30610616
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of circular RNAs, transforming growth factor-β, and long noncoding RNAs in hepatocellular carcinoma.
Shang W; Adzika GK; Li Y; Huang Q; Ding N; Chinembiri B; Rashid MS; Machuki JO
Cancer Med; 2019 Nov; 8(15):6684-6699. PubMed ID: 31523930
[TBL] [Abstract][Full Text] [Related]
15. ncRNA-mediated fatty acid metabolism reprogramming in HCC.
Xu K; Xia P; Chen X; Ma W; Yuan Y
Trends Endocrinol Metab; 2023 May; 34(5):278-291. PubMed ID: 36890041
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
17. The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma.
Yang X; Xie X; Xiao YF; Xie R; Hu CJ; Tang B; Li BS; Yang SM
Cancer Lett; 2015 May; 360(2):119-24. PubMed ID: 25721084
[TBL] [Abstract][Full Text] [Related]
18. Non-coding RNA-directed therapeutics in lung cancer: Delivery technologies and clinical applications.
Abdellatif AAH; Scagnetti G; Younis MA; Bouazzaoui A; Tawfeek HM; Aldosari BN; Almurshedi AS; Alsharidah M; Rugaie OA; Davies MPA; Liloglou T; Ross K; Saleem I
Colloids Surf B Biointerfaces; 2023 Sep; 229():113466. PubMed ID: 37515959
[TBL] [Abstract][Full Text] [Related]
19. Noncoding RNAs in cancer therapy resistance and targeted drug development.
Wang WT; Han C; Sun YM; Chen TQ; Chen YQ
J Hematol Oncol; 2019 Jun; 12(1):55. PubMed ID: 31174564
[TBL] [Abstract][Full Text] [Related]
20. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
